Ir al contenido principal

Deficiencia de beta hex

Aviso sobre el contenido

Esta página no se ha revisado recientemente, por lo que es posible que haya cambiado parte de la información o que algunos enlaces externos ya no funcionen.

Profesionales Médicos

Los artículos de Referencia Profesional están diseñados para ser utilizados por profesionales de la salud. Están escritos por médicos del Reino Unido y se basan en evidencia de investigación, así como en guías del Reino Unido y Europa. Puede encontrar uno de nuestros artículos de salud más útil.

Synonyms: Sandhoff's disease, type II GM2 gangliosidosis, hexosaminidase A and B deficiency

Descripción1

The GM2 gangliosidoses are a group of lipid storage diseases caused by a mutation in at least one of three recessive genes: HEXA, HEXB or GM2A. The products of all 3 genes are required for normal catabolism of the GM2 ganglioside substrate. Abnormal catabolism of this substrate results in accumulation of the substrate inside neuronal lysosomes, leading to cell death, most significantly in the brain and spinal cord.

The products of the 3 genes HEXA, HEXB and GM2A are respectively:

  • Alpha subunits of b-hexosaminidase A: absence or defects of these results in Enfermedad de Tay-Sachs (TSD) and its variants.

  • Beta subunits of Hex A: absence or defects of these results in Sandhoff's disease (SD) and its variants.

  • GM2 activator protein.

Different mutations give rise to different clinical phenotypes. TSD is the most common of the GM2 gangliosides. Where there are abnormal beta chains both hexosaminidase A and B will be affected. With combined enzyme deficiency, there is more extensive extraneural involvement.

This article is about the latter group of patients, where there is a mutation of the HEXB gene leading to a deficiency of the beta subunit of Hex A and the subunits of Hex B leading to a spectrum of disorders including SD. Patients with these diseases tend to present with developmental delay and progressive neurodegenerative disorders.

Epidemiología2

  • This is a rare group of disorders affecting approximately 3.22 per million non-Jewish newborns (compared with 1 in a million Jewish newborns - a distinction with TSD where there is an increased prevalence in the Ashkenazi Jewish community).

  • Los hombres y las mujeres se ven igualmente afectados.

  • Clusters of affected children have occurred in Argentina, Portugal,3 Cyprus (the Maronite community has been highlighted as being at particular risk).12 and the Lebanon. In the USA, those with an Italian ancestry have been found to be at higher risk of being a carrier for Sandhoff's disease (SD).4

  • This group of disorders is transmitted as single gene autosomal-recessive disorders; consanguinity increases risk.

Presentación25

The syndrome usually presents in infancy (typically at about 6 months of age) or in early childhood with signs of:

  • Developmental delay and neuromuscular problems: floppy baby, distonía, ataxia, muscle wasting, myoclonus, convulsiones.

  • Ophthalmological problems: cherry red spots seen at the macula, early ceguera.

  • They may appear to have a 'doll-like' facial appearance.

  • Extraneural involvement: frequent infecciones respiratorias, mild visceromegaly, occasional foamy histiocytes or vacuolated lymphocytes in peripheral blood.

There are juvenile and adult forms which show delayed onset (between 2 and 10 years old or in adulthood respectively),1 slower progress and longer survival.6

Diagnóstico diferencial

  • Other lipid storage diseases such as Tay-Sachs disease.

  • Enfermedad de Gaucher.

  • Motor skills disorder.

  • The mucopolysaccharidoses.

  • Síndrome de Hurler.

  • Ataxia de Friedreich.

  • Enfermedad de Niemann-Pick.

Investigaciones

  • Beta Hex enzyme assay can be undertaken in specialist centres. Hexosaminidase activity can be measured in serum, leukocytes, tears and cultivated fibroblasts.

  • DNA typing will confirm the diagnosis.

  • Periodic acid-Schiff (PAS) staining of systemic tissues will differentiate Sandhoff's disease from the other GM2 gangliosidoses.

Manejo

  • There is currently no specific treatment for patients with these diseases.

  • Treatment is supportive (eg concentration on nutrition, hydration, airway support) and symptomatic (eg anticonvulsivos where fitting, treatment of respiratory infections).

Complicaciones

Frequent respiratory infections are a common complication.

Pronóstico

In general terms, the earlier the presentation, the worse the prognosis. The prognosis for all forms of beta Hex deficiency is poor, with most sufferers dying in childhood. Neonates appear normal but increasing motor weakness is usually evident by about age 6 months. Loss of the swallowing reflex will make the child more vulnerable to aspiration and infecciones respiratorias. Commonly, death occurs by about the age of 4 years.

Prevención

Asesoramiento genético - prenatal diagnosis and carrier status can be determined where mutations are known.

Actualizaciones exclusivas para profesionales de la salud

Mantente informado con las últimas actualizaciones clínicas, perspectivas profesionales y orientación basada en evidencia. El boletín de Patient Pro selecciona contenido esencial para profesionales de la salud, entregado directamente en tu bandeja de entrada.

Por favor, introduce una dirección de correo electrónico válida

Al suscribirte aceptas nuestros Política de Privacidad. Puedes darte de baja en cualquier momento. Nunca vendemos tus datos.

Lecturas adicionales y referencias

  1. Tegay DH; GM2 Gangliosidoses, eMedicine, Nov 2009
  2. Sandhoff Disease, Online Mendelian Inheritance in Man (OMIM), 2007
  3. Pinto R, Caseiro C, Lemos M, et al; Prevalence of lysosomal storage diseases in Portugal.; Eur J Hum Genet. 2004 Feb;12(2):87-92.
  4. Branda KJ, Tomczak J, Natowicz MR; Heterozygosity for Tay-Sachs and Sandhoff diseases in non-Jewish Americans with ancestry from Ireland, Great Britain, or Italy.; Genet Test. 2004 Summer;8(2):174-80.
  5. Textbook of Paediatrics, 6th Edition Forfar and Arneil 2003 Churchill Livingstone ISBN 0443071926
  6. Cashman NR, Antel JP, Hancock LW, et al; N-acetyl-beta-hexosaminidase beta locus defect and juvenile motor neuron disease: a case study.; Ann Neurol. 1986 Jun;19(6):568-72.

Historial del artículo

La información en esta página está escrita y revisada por pares por clínicos calificados.

Farmacia en línea, tratamientos y servicios de salud

Acceso sencillo a tratamientos y servicios de salud confiables en línea.

Common conditions

Get help with common conditions through the NHS, without a GP appointment.

Book your free Pharmacy First appointment